Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Study of Sorafenib, Valproic Acid, and Sildenafil in the Treatment of Recurrent High-Grade Glioma

NCT01817751 is registered in ClinicalTrials.gov with Virginia Commonwealth University as lead sponsor.

NCT NCT01817751
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01817751 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Study of Sorafenib, Valproic Acid, and Sildenafil in the Treatment of Recurrent High-Grade Glioma
Lead sponsor
Virginia Commonwealth University
Phase
Phase 2
Overall status
Completed
Start date
April 11, 2013
Completion date
May 12, 2023
Enrollment
47 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma, malignant glioma, recurrent adult brain neoplasm, who grade iii glioma